Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Psoriasis Review

Deepen your understanding of the field

The IPC Psoriasis Review provides practicing physicians with an authoritative research review that targets a range of key psoriasis publications most relevant to current clinical practice. The newsletter leverages the collective research and clinical expertise of IPC’s Councilors to identify the most important publications in psoriasis from the past year and provide a concise editorial commentary on the value of these publications.

2019

July 2019 | Issue 15 | Number 2

Biologics, Biosimilars, Cardiovascular, Clinical trials, Comorbidities, Early Intervention, Epidemiology, Immunology, Pediatric, Registries, Research, Systemic therapies

This issue includes:

  • Semi-annual review of the Top Five Papers in psoriasis research
  • Symposium report: Cardiovascular disease in psoriasis: A changing paradigm
  • Symposium report: Challenging cases: A focus on pediatrics, comorbidities, infections, & biologics
  • IPC news
  • Educational events & clinical resources

Co-Editors

  • Andrew Y. Finlay, MBBS, FRCP, dermatology professor, Cardiff University, Cardiff, United Kingdom
  • Marcus Schmitt-Egenolf, MD, PhD, dermatology professor at Umeå University, Umeå, Sweden

PDF available for download:

English Version



2019

January 2019 | Issue 15 | Number 1

Clinical trials

This issue includes:

  • Semi-Annual Review of the Top Five Papers in Psoriasis Research
  • Focus on Psoriasis: P4 Medicine
  • IPC News

Co-Editors

  • Clay J. Cockerell, MD, founder/medical director, Cockerell Dermapathology, Dallas, United States
  • Gail Todd, BSc (Agric), MBChB, FFDerm (SA), PhD, Emeritus Professor, Department of Medicine, University of Cape Town, South Africa

PDF available for download:

English Version
Spanish Version
Portugese Version
Chinese Version

Search Reviews:

Filter by Topic:


In the latest

Psoriasis Review

IPC's bi-annual review of the latest news in the field of psoriasis.

 

read the latest issue

UPCOMING EVENT

The mechanistic model(s) of psoriasis: Autoimmune and/or inflammatory?

Wednesday, September 18, 2019
2:00 pm - 6:00 pm
Bordeaux, france
Register Now

Psoriasis News

8/20/2019 10:08:00 AM
Eli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).
8/6/2019 11:36:00 AM
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
8/1/2019 7:19:00 AM
On 25 May 2019, the World Health Assembly officially adopted the eleventh revision of the International Classification of Diseases (ICD-11). The ICD-11 will come into effect on 1 January 2022.
8/1/2019 7:09:00 AM
Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab)i , for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. Please see full indications and Boxed Warning for HADLIMA™, below.
More News

This website uses cookies. Please ensure your cookies are enabled. 
OK